|
Intraocular pressure disorder
|
0.030 |
Biomarker
|
disease |
BEFREE |
<b>Abbreviations</b>: BCVA: best corrected visual acuity; BMI: body mass index; CDR: cup-to-disc ratio; EDTA: ethylenediaminetetraacetic acid; ELISA: enzyme-linked immunosorbent assay; ESR: erythrocyte sedimentation rate; HVF: Humphrey visual field; IOP: intraocular pressure; KPro G: keratoprosthesis with glaucoma; KPro NoG: keratoprosthesis without glaucoma; KPro: keratoprosthesis; MD: mean deviation; NA: narrow angle; non-KPro: without keratoprosthesis; PACG: primary angle closure glaucoma; RNFL: retinal nerve fiber layer; TNF-α: tumor necrosis factor alpha; TNFR1: tumor necrosis factor receptor 1; TNFR2: tumor necrosis factor receptor 2.
|
30632412 |
2019 |
|
Glaucoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
<b>Abbreviations</b>: BCVA: best corrected visual acuity; BMI: body mass index; CDR: cup-to-disc ratio; EDTA: ethylenediaminetetraacetic acid; ELISA: enzyme-linked immunosorbent assay; ESR: erythrocyte sedimentation rate; HVF: Humphrey visual field; IOP: intraocular pressure; KPro G: keratoprosthesis with glaucoma; KPro NoG: keratoprosthesis without glaucoma; KPro: keratoprosthesis; MD: mean deviation; NA: narrow angle; non-KPro: without keratoprosthesis; PACG: primary angle closure glaucoma; RNFL: retinal nerve fiber layer; TNF-α: tumor necrosis factor alpha; TNFR1: tumor necrosis factor receptor 1; TNFR2: tumor necrosis factor receptor 2.
|
30632412 |
2019 |
|
Ulcerative Colitis
|
0.600 |
Biomarker
|
disease |
BEFREE |
<b>Aims:</b> To evaluate the cost differences between a treatment strategy including tofacitinib (TOFA) vs treatment strategies including adalimumab (ADA), golimumab (GOL), infliximab (IFX), and vedolizumab (VEDO) among all patients with moderate-to-severe ulcerative colitis (UC) (further stratified by patients naïve/exposed to tumor necrosis factor inhibitors [TNFis]).
|
31012362 |
2019 |
|
Cerebrovascular accident
|
0.600 |
Biomarker
|
group |
BEFREE |
<b>Background:</b> Tumor necrosis factor-a-induced protein 8-like 2 (TIPE2) is a novel regulator of immunity and protects against experimental stroke.
|
30588195 |
2018 |
|
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
<b>Background:</b> This study sought to evaluate the efficacy of a novel intraoperative chemotherapy (IOC) regimen that consists of hydroxycamptothecin, tumor necrosis factor (TNF), 5-fluorouracil (5-FU), and calcium folinate (CF) on the outcomes of colorectal cancer (CRC).
|
31762808 |
2019 |
|
Polycystic Ovary Syndrome
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
<b>Conclusion</b> Relative to the control group, endometrial flushing fluid TNF-α levels were significantly higher in endometrioma patients and IL-2 levels were significantly lower in PCOS, leiomyoma and endometrioma patients.
|
31148852 |
2019 |
|
Rheumatoid Arthritis
|
0.700 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion</b>: TNFα antagonists are used less often and glucocorticoids more often in elderly patients with active RA compared to their younger counterparts.
|
30230962 |
2018 |
|
Sepsis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
<b>Conclusion</b> We uncovered an association between IL-10 1082 gene variation and sepsis in VLBW infants but did not identify associations between neonatal sepsis and TNF-α 308 or IL-6 gene variation.
|
27960200 |
2017 |
|
Septicemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
<b>Conclusion</b> We uncovered an association between IL-10 1082 gene variation and sepsis in VLBW infants but did not identify associations between neonatal sepsis and TNF-α 308 or IL-6 gene variation.
|
27960200 |
2017 |
|
Sepsis of the newborn
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
<b>Conclusion</b> We uncovered an association between IL-10 1082 gene variation and sepsis in VLBW infants but did not identify associations between neonatal sepsis and TNF-α 308 or IL-6 gene variation.
|
27960200 |
2017 |
|
Bacterial sepsis of newborn
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
<b>Conclusion</b> We uncovered an association between IL-10 1082 gene variation and sepsis in VLBW infants but did not identify associations between neonatal sepsis and TNF-α 308 or IL-6 gene variation.
|
27960200 |
2017 |
|
Rheumatoid Arthritis
|
0.700 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion:</b> A fresh look at the evidence highlights that TNF-I might be associated with ILD adverse events in RA, which can induce more severe pulmonary symptoms and even result in death.
|
31308625 |
2019 |
|
anaphylaxis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
<b>Conclusion:</b> As such, we proposed that through meta-analysis, the potential soluble mediators involved in rodent IgG-mediated anaphylaxis to be histamine, PAF, β-hexosaminidase, IL-6 and-13 and MIP-1α, and TNF-α but will require further studies with larger sample size.
|
30809224 |
2019 |
|
Acute pulmonary thromboembolism
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
<b>Conclusion:</b> Our findings suggested that MCP-1 was involved in the formation of TNF-α-induced inflammatory response, and resveratrol could down-regulate the expression of MCP-1 via TNF-α- inhibition, which might contribute to the decline of acute PTE-induced PH in vivo.
|
31213772 |
2019 |
|
Sepsis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
<b>Conclusion:</b> UTI effectively protects TJs and helps to attenuate the permeability of pulmonary capillary endothelial cells during sepsis through inhibiting NF-κB and MAPKs signal pathways and TNF-α expression.
|
30150933 |
2018 |
|
Septicemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
<b>Conclusion:</b> UTI effectively protects TJs and helps to attenuate the permeability of pulmonary capillary endothelial cells during sepsis through inhibiting NF-κB and MAPKs signal pathways and TNF-α expression.
|
30150933 |
2018 |
|
Ataxia Telangiectasia
|
0.020 |
Biomarker
|
disease |
BEFREE |
<b>Conclusions:</b> Granulomas in A-T progress slowly over years and can lead to significant morbidity.Treatment with TNF inhibitors was safe and in part successful in our patients.
|
30279689 |
2018 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
<b>Conclusions:</b> In a long-term real-life setting, drug survival of UST is better than that of TNF-a inhibitors for both biologic-naive and biologic-experienced patients with psoriasis.
|
29848153 |
2019 |
|
Sepsis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
<b>Expert opinion</b>: TNFα antagonists may be more immunosuppressive than non-TNF-targeted biologic agents and increase the risk of systemic infections.
|
31322018 |
2019 |
|
Inflammatory Bowel Diseases
|
0.600 |
Biomarker
|
group |
BEFREE |
<b>Introduction</b>: Tumor necrosis factor-α (TNF-α)-blocking agents are drugs approved for the treatment of inflammatory bowel diseases (IBDs).
|
31490707 |
2019 |
|
Neurodegenerative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
<b>Introduction</b>: The importance of excessive cerebral tumor necrosis factor (TNF) concentrations as one of the central tenets of the pathogenesis of the neurodegenerative diseases is now widely known, but variably accepted.
|
31092047 |
2019 |
|
Rheumatoid Arthritis
|
0.700 |
Biomarker
|
disease |
BEFREE |
<b>Introduction</b>: Treatment of rheumatoid arthritis (RA) has been revolutionized by the introduction of biologic disease-modifying antirheumatic drugs, such as tumor necrosis factor (TNF) inhibitors.
|
31801395 |
2019 |
|
Dermatologic disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
<b>Introduction:</b> The aim of this study was to present the follow-up results of 110 patients who were given anti-tumor necrosis factor alpha (TNF-α) therapy for rheumatic and dermatologic diseases in a country with a high rates of active and latent tuberculosis bacillus infection.
|
31615316 |
2019 |
|
Bacillus infection
|
0.010 |
Biomarker
|
disease |
BEFREE |
<b>Introduction:</b> The aim of this study was to present the follow-up results of 110 patients who were given anti-tumor necrosis factor alpha (TNF-α) therapy for rheumatic and dermatologic diseases in a country with a high rates of active and latent tuberculosis bacillus infection.
|
31615316 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
<b>K1</b> serves to downregulate various cancer survival signaling pathways (AKT, p38, IL-6, VEGF, and TNF-α) and upregulate an anti-inflammatory response (IL-10).
|
31509395 |
2019 |